{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:14:50Z","timestamp":1759961690659,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12028-021-01378-y","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T17:02:40Z","timestamp":1635786160000},"page":"922-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Induced Hypertension or Intravenous Milrinone for Cerebral Vasospasm: Why Choose?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5311-3987","authenticated-orcid":false,"given":"Karim","family":"Lakhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Rozec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Cadiet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-021-01331-z","author":"K Lakhal","year":"2021","unstructured":"Lakhal K, Hivert A, Alexandre P-L, Fresco M, Robert-Edan V, Rodie-Talbere P-A, et al. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage: the MILRISPASM controlled before-after study. Neurocrit Care. 2021. https:\/\/doi.org\/10.1007\/s12028-021-01331-z.","journal-title":"Neurocrit Care"},{"key":"1378_CR2","unstructured":"Abulhasan YB, Ortiz Jimenez J, Teitelbaum J, Angle MR. Role of induced hypertension and intravenous milrinone after aneurysmal subarachnoid hemorrhage: is it time to shift the paradigm? Neurocrit Care Press."},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","volume":"15","author":"MN Diringer","year":"2011","unstructured":"Diringer MN, Bleck TP, Claude Hemphill J, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society\u2019s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211\u201340.","journal-title":"Neurocrit Care"},{"key":"1378_CR4","first-page":"168","volume":"32","author":"LJ Velly","year":"2015","unstructured":"Velly LJ, Bilotta F, Fabregas N, Soehle M, Bruder NJ, Nathanson MH. Anaesthetic and ICU management of aneurysmal subarachnoid haemorrhage: a survey of European practice. Eur J Anaesthesiol. 2015;32:168\u201376.","journal-title":"Eur J Anaesthesiol"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/STROKEAHA.117.017956","volume":"49","author":"CS Gathier","year":"2018","unstructured":"Gathier CS, van den Bergh WM, van der Jagt M, Verweij BH, Dankbaar JW, M\u00fcller MC, et al. Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a randomized clinical trial. Stroke. 2018;49:76\u201383.","journal-title":"Stroke"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-021-01378-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T14:19:41Z","timestamp":1640096381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-021-01378-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s12028-021-01378-y","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"type":"print","value":"1541-6933"},{"type":"electronic","value":"1556-0961"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karim Lakhal has no conflicts of interest in connection with the work submitted. In addition, during the past 3\u00a0years, KL received congress registration fees from Sanofi-Aventis (once in 2018), travel fees from MSD France (once in 2017), Gilead Sciences (once in 2017), Pfizer (three times: in 2019, 2020, and 2021), and Correvio Pharma (twice in 2020, once\u00a0in 2021). Bertrand Rozec has no conflicts of interest in connection with the work submitted. In addition, during the past 5\u00a0years, BR received lecture fees from Fisher & Paykel, Baxter International, LFB, Aspen, research grants from Baxter, and consulting fees from LFB and AstraZeneca. None of the other authors have any financial or nonfinancial competing interest in connection with this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}